Targeting CD24 as a novel immunotherapy for solid cancers

Cluster of differentiation 24 (CD24), a mucin-like highly glycosylated molecule has been extensively studied as a cancer stem cell marker in a variety of solid cancers. The functional role of CD24 is either fulfilled by combining with ligands or participating in signal transduction, which mediate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yan, Zhu, Guangming, Yang, Li, Yang, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623753/
https://www.ncbi.nlm.nih.gov/pubmed/37919766
http://dx.doi.org/10.1186/s12964-023-01315-w
_version_ 1785130801765023744
author Yang, Yan
Zhu, Guangming
Yang, Li
Yang, Yun
author_facet Yang, Yan
Zhu, Guangming
Yang, Li
Yang, Yun
author_sort Yang, Yan
collection PubMed
description Cluster of differentiation 24 (CD24), a mucin-like highly glycosylated molecule has been extensively studied as a cancer stem cell marker in a variety of solid cancers. The functional role of CD24 is either fulfilled by combining with ligands or participating in signal transduction, which mediate the initiation and progression of neoplasms. Recently, CD24 was also described as an innate immune checkpoint with apparent significance in several types of solid cancers. Herein, we review the current understanding of the molecular fundamentals of CD24, the role of CD24 in tumorigenesis and cancer progression, the possibility as a promising therapeutic target and summarized different therapeutic agents or strategies targeting CD24 in solid cancers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-023-01315-w.
format Online
Article
Text
id pubmed-10623753
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106237532023-11-04 Targeting CD24 as a novel immunotherapy for solid cancers Yang, Yan Zhu, Guangming Yang, Li Yang, Yun Cell Commun Signal Review Cluster of differentiation 24 (CD24), a mucin-like highly glycosylated molecule has been extensively studied as a cancer stem cell marker in a variety of solid cancers. The functional role of CD24 is either fulfilled by combining with ligands or participating in signal transduction, which mediate the initiation and progression of neoplasms. Recently, CD24 was also described as an innate immune checkpoint with apparent significance in several types of solid cancers. Herein, we review the current understanding of the molecular fundamentals of CD24, the role of CD24 in tumorigenesis and cancer progression, the possibility as a promising therapeutic target and summarized different therapeutic agents or strategies targeting CD24 in solid cancers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-023-01315-w. BioMed Central 2023-11-02 /pmc/articles/PMC10623753/ /pubmed/37919766 http://dx.doi.org/10.1186/s12964-023-01315-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Yang, Yan
Zhu, Guangming
Yang, Li
Yang, Yun
Targeting CD24 as a novel immunotherapy for solid cancers
title Targeting CD24 as a novel immunotherapy for solid cancers
title_full Targeting CD24 as a novel immunotherapy for solid cancers
title_fullStr Targeting CD24 as a novel immunotherapy for solid cancers
title_full_unstemmed Targeting CD24 as a novel immunotherapy for solid cancers
title_short Targeting CD24 as a novel immunotherapy for solid cancers
title_sort targeting cd24 as a novel immunotherapy for solid cancers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623753/
https://www.ncbi.nlm.nih.gov/pubmed/37919766
http://dx.doi.org/10.1186/s12964-023-01315-w
work_keys_str_mv AT yangyan targetingcd24asanovelimmunotherapyforsolidcancers
AT zhuguangming targetingcd24asanovelimmunotherapyforsolidcancers
AT yangli targetingcd24asanovelimmunotherapyforsolidcancers
AT yangyun targetingcd24asanovelimmunotherapyforsolidcancers

Ejemplares similares